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Mesangial cells release untransformed prostaglandin H2
as a major prostanoid
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Mesangial cells release untransformed prostaglandin H2 as a PGs and TXs play a relevant role in the control of renal
major prostanoid. function [1]. Prostanoids regulate both glomerular hemo-
Background. Prostaglandin H2 (PGH2) is the precursor of dynamics and epithelial water and solute transport. COXthe other prostanoids and exhibits a vasoconstricting activity.
is the first enzyme in the biosynthesis of prostanoids af-Glomerular mesangial cells are an important source of vaso-
active prostanoids in kidney. Hence, the present investigation ter release of free AA from phospholipids by the actions
focused on the release of untransformed PGH2 by rat glomeru- of phospholipases. Two COX isoforms have been de-
lar mesangial cells (RGMCs). scribed. COX-1 is expressed in a constitutive manner,Methods. Synthesis of prostanoid by resting and interleukin-
and COX-2 is the isoenzyme inducible by mitogens and1b (IL-1b)-treated (overnight) RGMCs from exogenous or
is overexpressed in inflammatory processes [2]. As op-endogenous arachidonic acid (AA) was assessed by high-perfor-
mance liquid chromtography or enzyme immunoassay, respec- posed to other tissues, the relatively abundant COX-2
tively. Cyclo-oxygenase isoforms were determined by Western expression is detected constitutively in the kidney [3, 4].blotting. Release of untransformed PGH2 from exogenous AA COX catalyzes the transformation of AA to PGH2, whichwas evaluated in RGMCs and intact glomeruli as the difference
is the pivotal intermediate in the biosynthesis of theof PGF2a formed in the incubations performed in the presence
and in the absence of SnCl2 or measuring the ability of aspirin- other active prostanoids, PGE2, PGF2a, PGD2, and TXA2.
treated platelets to form thromboxane B2 (TXB2) in mixed Prostacyclin-synthase [prostaglandin I-synthase (PGIS)]incubations of platelets and RGMCs or glomeruli.
catalyzes the subsequent transformation of PGH2 intoResults. The prostanoids formed by RGMCs were PGE2,
PGF2a, PGI2 and PGD2. SnCl2 totally deviated formation of PGE2 the potent vasodilator PGI2 [5, 6]. Conversion of PGH2
and PGD2 toward PGF2a in resting RGMCs, whereas PGE2 was into the potent vasoconstrictor TXA2 is always catalyzed
only partially deviated toward PGF2a in IL-1b–treated RGMCs. by the TXA synthase [7]. In contrast, isomerization ofThe PGE2/PGD2 ratio in resting RGMCs was similar to that ex-
PGH2 to PGE2 and PGD2 may occur either spontane-pected for nonenzymatic isomerization of PGH2, whereas this
ratio was higher in IL-1b–treated RGMCs, suggesting the in- ously [8] or enzymatically catalyzed by PGE synthase
duction of PGE synthase by IL-1b. Aspirin-treated platelets (PGES) and PGD synthase [9, 10]. Available data show
formed TXB2 when either RGMCs or intact glomeruli were that at least three renal tissues contain COX activitypresent in the incubation and formation of TXB2 was approxi-
and are capable of prostanoid biosynthesis: the vascularmately fourfold higher with IL-1b–treated RGMCs or glo-
meruli. compartment, the collecting duct cells, and the medullary
Conclusions. RGMCs and intact glomeruli released substan- interstitial cells. Isolated glomeruli, glomerular epithelial
tial amounts of untransformed PGH2, which was enhanced fol- cells, and glomerular mesangial cells produce PGE2 andlowing exposure to IL-1b.
PGF2a as the main prostanoids, whereas renal vascular
tissue produces mainly PGI2 [reviewed in 1].
We reported that endothelial cells are able to releaseProstanoids are a diverse family of compounds which
a large quantity of untransformed PGH2 depending onincludes prostaglandins (PGs) and thromboxanes (TXs)
the ratio of COX to PGIS activity, due to the fact thatderived from arachidonic acid (AA) through the cyclo-
these are probably the only enzymes involved in prostan-oxygenase (COX; also termed PGH synthase) pathway.
oid release in endothelial cells [11–13]. PGH2 is not only
the precursor of all other active prostanoids, but alsoKey words: vasoactive prostanoids, glomerular mesangial cells, cyclo-
oxygenase, hemodynamics. exhibits strong constricting and platelet-activating prop-
erties since both TXA2 and PGH2 share the same recep-Received for publication May 22, 2000
tor [14]. The PGH2 role in kidney has not yet beenand in revised form October 23, 2000
Accepted for publication October 26, 2000 explored, in part because of the analytical difficulties
since, like TXA2 and PGI2, it is very unstable. Neverthe-Ó 2001 by the International Society of Nephrology
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less, in contrast with that which occurs with TXA2 and Culture and treatment of human dermal fibroblasts
PGI2, PGH2 does not yield a single stable final compound. Human dermal fibroblasts were isolated and cultured
Since glomerular mesangial cells are an important source as described previously [19]. Cells in passages 4 through
of prostanoids in glomerulus, the present investigation 6 were maintained with 1% FBS for 24 hours prior to
studied the release of untransformed PGH2 by mesangial treatment with 10 U/mL IL-1b overnight.
cells in the resting and stimulated states.
Formation of prostanoids from exogenous
AA by RGMCsMETHODS
After the indicated treatment, cells were incubatedPreparation of rat glomeruli suspensions and rat
at 378C in 0.5 mL RPMI 1640 containing 25 mmol/Lglomerular mesangial cells culture and treatment
[14C]-AA ([1-14C]-AA, 55 to 58 mCi/mmol; Amersham
Glomeruli were isolated from kidneys of 200 to 250 g Pharmacia Biotech Europe GmbH, Freiburg, Germany).
male Sprague-Dawley rats and rat glomerular mesangial After 10 minutes, the reactions were stopped by adding
cells (RGMCs) cultured as described [15]. Briefly, renal one volume cold solution of 2% acetic acid in methanol.
cortical tissue was pressed and rinsed with Hank’s bal- Samples were kept at 2808C until analysis. High-perfor-
anced salt solution (HBSS) through a nylon mesh (pore mance liquid chromatography (HPLC) analysis of eico-
size 100 mm; Becton Dickinson, Bedford, MA, USA), sanoids was performed as previously described [20].
and glomeruli were collected on a second nylon mesh
(pore size 70 mm). To perform experiments with intact Release of prostanoids from endogenous
glomeruli, these were suspended in RPMI 1640 medium AA by resting and IL-1b–treated RGMCs
and counted microscopically. To perform RGMC cul- Cells were incubated at 378C with 2 mL of RPMI 1640
tures, glomeruli were exposed to 0.1% collagenase containing 1% FBS and 100 U/mL IL-1b overnight, and
(Roche Molecular Biochemicals, Basilea, Switzerland), the supernatants were kept at 2808C until the analysis
the glomeruli were placed in 25 cm2 plastic tissue culture
of 6-oxo-PGF1a, PGE2, and PGF2a by specific enzyme im-flasks (TPP, Trasadingen, Switzerland) and cultured in
munoassay (EIA; 6-oxo-PGF1a, and PGE2 from Amer-tissue culture medium composed of RPMI 1640 supple-
sham Pharmacia Biotech Europe GmbH; PGF2a frommented with L-glutamine 2 mmol/L, penicillin 100 U/mL,
Cayman Chemicals, Ann Arbor, MI, USA).streptomycin 100 mg/mL, and 10% fetal bovine serum
(FBS; all from Biological Industries, Kibbutz Bert Hae- Western blotting of COX-1 and COX-2
mek, Israel). RPMI 1640 medium containing puromycin
After the indicated treatment, lysates of RGMC wereaminonucleoside was used to prevent contamination by
prepared as previously described [21]. Total protein equiv-epithelial cells in the first passage; modified Eagle’s me-
alents of each sample were subjected to sodium dodecyldium (MEM) culture medium containing D-Val instead
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)of L-Val (GIBCO BRL, Life Technologies S.A., Barce-
and transferred to polyvinylidene difluoride membraneslona, Spain) was used to prevent contamination by fibro-
(Immobilon-P; Millipore Ibe´rica, Barcelona, Spain). Block-blasts, also in the first passage [16].
ing the nonspecific binding of the antibody was per-Identification as mesangial cells was confirmed by us-
formed by treating the membrane with 10% wt/vol non-ing the indirect peroxidase method to detect staining for
fat dried milk in 50 mmol/L Tris HCl, pH 7.4, containingvimentin (Roche Molecular Biochemicals). Mesangial cell
150 mmol/L NaCl overnight at 48C. Membranes wereF-actin was visualized using rhodamine-conjugated phal-
then incubated with a specific monoclonal antibody forloidin. The cells were negative for cytokeratin (Sigma-
COX-1 (catalog no. 160110; Cayman Chemical), whichAldrich, Madrid, Spain) excluding epithelial contamina-
raised against purified ovine COX-1, and a polyclonaltion [17, 18].
antibody for COX-2, which was raised against syntheticTo perform experiments with RGMCs, cells were seeded
peptide from the murine COX-2 sequence (amino acidsinto six-well plates and allowed to grow to confluence.
584-598-SHSRLDDINPTVLIK; catalog no. 160116; Cay-The cells were then maintained with 1% FBS for 24
man Chemical). Information supplied by the manufac-hours prior to addition (or not) of 100 U/mL human
turer indicated that anti–COX-1 has positive cross-reac-recombinant IL-1b (50,000 U/mg, purity .98%; Roche
tivity with ovine, human, bovine, rat, and murine COX-1;Molecular Biochemicals) and maintained in these condi-
ovine COX-2 (5 to 10%) and anti–COX-2 have positivetions overnight until further incubations to evaluate
cross-reactivity with murine, ovine, human, rabbit, rat, andprostanoid release. Experiments were performed on cell
monkey COX-2. No cross-reactivity with COX-1 frompassages 4 to 10. To perform experiments with intact glo-
any species was detected. Positive controls were per-meruli, suspensions were treated or not with 100 U/mL
formed by using isolated COX-1 from ram seminal vesi-human recombinant IL-1b overnight until further incu-
bations to evaluate the prostanoid release. cles or COX-2 purified from sheep placenta (Cayman
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Table 1. Prostanoid formation by resting and IL-1b-stimulated RGMC
Prostanoid
Stimulus AA source 6-oxo-PGF1a PGF2a PGE2 PGD2 HHT
Resting Exogenousa 30.361.5b 24.365.6 213.3666.7 50.8617.8 86.1625.4
Endogenousc 1.060.2 13.769.1 4.662.2 — —
IL-1b Exogenous 53.4617.1d 59.4624.1d 734.96308.9d 96.0642.9d 129.5642.7d
Endogenous 101.3626.7e 582.16212.9e 731.86296.3e — —
Abbreviations are: IL, interleukin; RGMC, rat glomerular mesangial cells; AA, arachidonic acid; PG, prostaglandin; HHT, 12-hydroxy-heptadeca trienoic acid.
a Cells treated or not with IL-1b overnight were incubated with 25 mmol [14C]-AA for 10 min
b pmol/106 cells, mean 6 SD, N 5 4 (exogenous), N 5 5 (endogenous)
c Prostanoids were determined in the supernatants of cells treated or not with IL-1b overnight
d P , 0.05 and e P , 0.001 when compared with resting cells
Chemical). Detection was performed by using the ECL PGH2, the difference of PGF2a peak between the samples
incubated with and without SnCl2 was evaluated. ForSystem (Amersham Pharmacia Biotech Europe GmbH)
comparative purposes, the same experiments were per-according to the manufacturer’s instructions. To estimate
formed with human dermal fibroblasts.the relative levels of each COX protein the films were
scanned in order to obtain digital images that were quan-
Statisticstitated as described previously [11].
Sigma-Stat software was used for statistical analysis.
Trapping of the endogenous AA-derived PGH2 Statistical significance between groups was assessed us-
released by RGMC and glomeruli ing the Student t test for two groups. One-way analysis
of variance (ANOVA) and the Student-Newman-KeusTrapping of PGH2 derived from endogenous AA was
test were used to compare more than two groups. A Pachieved by adding 50 mL of a platelet suspension con-
value below 0.05 was considered significant.taining 108 COX-inactivated platelets to the wells of rest-
ing and IL-1b–treated RGMCs. After incubation for 30
minutes at 378C, supernatants were removed and placed RESULTS
at 2808C until analysis of TXB2. To perform experiments Effect of IL-1b on metabolic profile of
with the intact glomeruli after treatment or not with AA in RGMCs
IL-1b, glomeruli were sedimented by centrifugation and
The results in Table 1 show that RGMCs incubatedresuspended (104 glomeruli/mL) in medium containing
with exogenous [14C]-AA produced PGE2 as a major pros-or not 108 COX-inactivated platelets, and processed as tanoid, and 6-oxo-PGF1a (final stable metabolite of PGI2),described for the RGMC experiments. Inactivation of PGF2a, and PGD2 as minor prostanoids; 12-hydroxy-hep-COX in the platelet suspensions was achieved by pre- tadeca trienoic acid (HHT) was also formed. No TXB2treatment with 200 mmol/L aspirin for 20 minutes, and was detected in any of the samples analyzed, either in
it was confirmed in each experiment by incubating 0.5 mL resting or in IL-1b–treated RGMCs. Therefore, PGE2,aliquots of the aspirin-treated platelet suspensions with 6-oxo-PGF1a and PGF2a were chosen to evaluate pro-25 mmol/L [14C]-AA at 378C for 10 minutes followed by stanoid synthesis from endogenous AA. From endoge-
high-pressure liquid chromatography (HPLC) analysis nous AA, PGE2 and PGF2a were the main prostanoids,of eicosanoids. and 6-oxo-PGF1a was formed to a lesser extent in both
resting and IL-1b–treated RGMCs.Effect of the SnCl2 on prostanoid pattern in RGMCs, Regarding the experiments of exogenous AA, resultsrat glomeruli, and human dermal fibroblasts
in Table 1, in which the same concentration of [14C]-AA
Prostaglandin H2 is an unstable PG that is converted was used for resting and IL-1b–treated cells, show that
into PGF2a by mild reducing agents such as SnCl2 [22]. IL-1b increased the ability of RGMCs to form all pros-
Therefore, to estimate the ratio of untransformed PGH2 tanoids. A twofold to threefold increase depending on
released by RGMC and intact glomeruli, the biologic prostanoid was observed and was consistent with the in-
material was treated or not with 100 U/mL IL-1b over- duction of COX-2 observed by Western blotting (Fig. 1).
night. After replacing the media, cells and glomeruli In untreated cells, the antibody against COX-1 recog-
were incubated at 378C in 0.5 mL medium RPMI 1640 nized a band of approximately 70 kD corresponding to
containing 25 mmol/L [14C]-AA in the presence or in the the migration of purified COX-1 from ram seminal vesi-
absence of 200 mg/mL SnCl2. After 10 or 30 minutes in cles. The antibody against COX-1 showed a slight cross-
the case of RGMC or glomeruli, respectively, the reac- reactivity with the band of COX-2 from sheep placenta.
tion was stopped as described previously in this article. The antibody against COX-2 did not detect the purified
Samples were kept at 2808C until analysis by HPLC as COX-1 from ram seminal vesicles and had scarce reac-
tion with protein band corresponding to COX-2 in un-described [20]. To estimate release of untransformed
Soler et al: Release of PGH2 by mesangial cells1286
presence of SnCl2 in IL-1b–treated glomeruli, and the
levels of PGF2a increased concomitantly.
These experiments were also performed with human
dermal fibroblasts that, in previous experiments, were
seen to express PGES by reverse transcription-polymer-
ase chain reaction (RT-PCR) [13]. In the IL-1b–treated fi-
broblasts, SnCl2 only caused a deviation of a small amount
of PGE2 toward PGF2a (Fig. 2). Formation of PGI2 was
not significantly modified by SnCl2 in any case. In resting
RGMCs, we found a ratio of PGE2 to PGD2 of 4.3 6
1.5. In contrast, IL-1b–treated RGMCs yielded a ratio
Fig. 1. Representative Western blots corresponding to the effect of
PGE2 to PGD2 of 8.1 6 1.3 (mean 6 SD, N 5 4).interleukin (IL)-1b on cyclooxygenase (COX)-1 and COX-2 expression
in rat glomerular mesangial cells (RGMCs). Cells were incubated with
100 U/mL IL-1b overnight. Cell lysates were subjected to Western Release of untransformed PGH2 from endogenous
blotting analysis as described in the Methods section. The optical density AA by RGMCs and rat glomeruli
of the COX-1 bands was 23.3 6 1.8 resting cells (control) vs. 23.0 6
5.5 IL-1b–treated cells (IL-1b), P 5 NS, and the optical density of the To observe whether RGMCs and whole glomeruli re-
COX-2 bands was 8.3 6 1.3 (control) vs. 45.5 6 4.94 (IL-1b), P , 0.001. leased untransformed PGH2 to the medium from endo-Data are mean 6 SD, N 5 3. Isolated COX-1 (from ram seminal vesicles)
genous substrate, resting and IL-1b–treated RGMCsand COX-2 (from sheep placenta) were used as positive controls.
and glomeruli were incubated for 30 minutes with 108
aspirin-treated platelets, and TXB2 was analyzed in the
supernatants. Results in Figure 3A show that TXB2
treated cells. In contrast, after overnight treatment with concentration in the incubations of RGMC alone was
IL-1b, the antibody against COX-2 recognized a protein very low. When aspirin-treated platelets were present in
band of approximately 70 kD corresponding to the mi- the incubation mixture of both untreated and IL-1b–
gration of purified COX-2 from sheep placenta. The stimulated RGMCs, levels of TXB2 were enhanced. Re-
densitometric analysis of the bands showed that IL-1b sults in Figure 3A indicate that exposure of RGMCs to
did not modify COX-1, whereas COX-2 protein levels IL-1b significantly increased transcellular formation of
were increased approximately fivefold. TXB2, indicating an enhanced release of PGH2. Similar
The effect of IL-1b on the accumulation of prostanoid results were obtained with the glomeruli suspensions
in the culture medium from endogenous AA (Table 1) (Fig. 3B). IL-1b also significantly increased transcellular
was greater than that from exogenous AA. A 42- to 160- formation of TXB2 in the incubations of isolated glomer-
fold increase depending on prostanoid when compared uli, indicating an enhanced release of PGH2. Although
with resting cells was observed, indicating an additional the increase in the release of untransformed PGH2
effect of IL-1b on phospholipase activity. caused by the treatment with IL-1b was similar in both
RGMCs and isolated glomeruli, the difference observed
Release of untransformed PGH2 from exogenous between incubations with and without platelets was
[14C]-AA by RGMCs and glomeruli
lower with glomeruli suspensions than with RGMCs.
The formation of PGI2 was only minimally modified
by the presence of SnCl2 in the medium of incubation
DISCUSSIONof RGMC with [14C]-AA. In contrast, PGE2 and PGD2
disappeared completely in the samples of resting RGMC As previously reported [23, 24], we also found that
RGMCs predominantly released PGE2 from both en-containing SnCl2 (data not shown). As chromatograms
in Figure 2 show, in IL-1b–treated RGMCs, PGD2 com- dogenous and exogenous AA. Nevertheless, the most
relevant finding was that large amounts of PGH2 formedpletely disappeared, whereas PGE2 was strongly but not
completely decreased in the presence of SnCl2, and the from endogenous substrate were also released by
RGMCs. Since TXB2 was not detected by HPLC whenlevels of PGF2a increased concomitantly. Suspensions of
isolated glomeruli were subjected to a similar experimen- RGMCs were incubated with labeled AA, we cannot
rule out the possibility that the small quantity of TXB2tal protocol to observe whether there was intact glomer-
uli release of untransformed PGH2 from exogenous AA. detected by EIA was an artifact caused by cross-reactiv-
ity of the antibody with other prostanoids. Indeed, onlyHPLC analysis (Fig. 2) shows that rat glomeruli pro-
duced PGE2 as the main prostanoid and small amounts trace amounts of TXA2 were reported to be released by
RGMCs in response to IL-1 [23]. In contrast, when as-of PGI2 and PGF2a, PGD2 and TXB2, if any, were below
the detection limit (about 250 cpm) even after treatment pirin-treated platelets, which were unable to form TXA2
from AA, were present together with RGMCs, substantialwith IL-1b. As was observed in RGMC incubations,
PGE2 was strongly but not completely decreased in the amounts of TXA2 were formed in 30 minutes. This sug-
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Fig. 2. Representative chromatograms of samples from IL-1b–treated RGMCs, whole glomeruli, or human dermal fibroblasts incubated with
[14C]-arachidonic acid (AA) in the absence and in the presence of SnCl2. RGMC or rat glomeruli were treated with IL-1b overnight, incubated
with 25 mmol/L of [14C]-AA for 10 or 30 minutes, respectively, with or without SnCl2, and analyzed by HPLC.
gests that RGMCs released untransformed PGH2, which and aspirin-treated platelets, indicating that untrans-
formed PGH2 was released by intact glomeruli also fromwas trapped by platelets. Release of untransformed
PGH2 was dramatically increased by the previous exposi- endogenous AA. It was notable that IL-1b increased the
release of untransformed PGH2 as in RGMCs. The facttion of RGMC to IL-1b, which was consistent with
COX-2 induction and with an enhanced phospholipase that the difference between samples with and without
platelets regarding levels of TXB2 was not so dramaticactivity [24]. HHT in platelets is formed by the action
of TX-synthase [25]. The ratio of HHT to TXB2 formed as it was in RGMCs could be due to a loss of TXA
synthase expression in mesangial cells during culturein our conditions was previously evaluated by incubating
suspensions of platelets untreated with aspirin with and/or TXA synthase is expressed in cells present in
glomerulus other than mesangial cells such as epithelial25 mmol/L [14C]-AA and determining both compounds
by HPLC. This ratio was 1.47 6 0.18 (mean 6 SD, N 5 cells and resident macrophages.
Prostaglandin D2 was a minor prostanoid when5). Taking this into account, we would like to point out
that the real quantity of PGH2 transformed by platelets RGMCs were incubated with labeled AA. PGD2 is a po-
sition isomer of PGE2 that may be synthesized fromwas actually more than twofold that showed in Figure
3. Release of untransformed PGH2 into the media was PGH2, not only enzymatically [10] but also spontane-
ously [8]. The fact that transformation of PGH2 intoalso observed in intact glomeruli since part of PGE2
formed from exogenous AA was diverted toward PGF2a PGD2 was completely diverted toward PGF2a in the pres-
ence of SnCl2 in both resting and IL-1b–treated RGMCin the presence of SnCl2, and transcellular formation of
TXB2 was observed in mixed incubations of glomeruli indicated that this prostanoid was formed nonenzymati-
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sults suggested that COX activity was not the limiting
step in the synthesis of PGE2 (and PGI2), and substantial
amounts of untransformed PGH2 were released by
RGMCs when incubated with exogenous AA.
Formation of PGF2a was only comparable to PGE2
when prostanoids were measured in the supernatant of
overnight incubations of RGMCs with IL-1b. However,
when exogenous AA was supplied, formation of PGE2
was more than tenfold higher than PGF2a. This was also
previously observed in endothelial cells [11]. The forma-
tion of PGF2a by two electron reduction of PGH2 could
occur nonenzymatically inside and outside the cells. Our
results are not conclusive with respect to this point. Nev-
ertheless, an electron donor-dependent reduction of
PGH2 into PGF2a is plausible. Hence, we can speculate
Fig. 3. TXB2 formed by aspirin-treated platelets from endogenous AA- that a slow turnover of such electron donor(s) couldderived PGH2 released by resting and IL-1b-treated RGMC (A) and
account for the predominant formation of PGF2a whenwhole glomeruli (B). Cell cultures and glomeruli suspensions were
incubated (IL-1b) or not (control) with 100 U/mL IL-1b overnight. the slow release of prostanoids caused by the presence
Culture medium was changed, and RGMCs or glomeruli were incubated of IL-1b was measured. In contrast, when an excess ofwithout (h) or with ( ) 108 aspirin-treated platelets at 378C for 30
exogenous AA was supplied, a large amount of PGH2minutes. TXB2 was analyzed in the supernatants by EIA. *P , 0.05
when compared with resting cells (control); #P , 0.05 and ##P , 0.001 was rapidly formed. As a consequence, this factor(s)
indicate statistical significance when compared with the homologous
could be rapidly depleted, thus limiting the transforma-samples without platelets. Data are mean 6 SD, N 5 6 for RGMCs
and N 5 4 for isolated glomeruli. tion of PGH2 into PGF2a. Under such conditions, PGE2
and PGD2 would be the predominant nonenzymatic
transformations of PGH2.
The present results suggest that RGMCs as well as
cally from PGH2 outside the cell. Isomerization of PGH2 intact glomeruli release substantial amounts of untrans-
to PGE2 cannot only occur enzymatically catalyzed by a formed PGH2. PGH2 binds to the TXA2 receptor [14],PGES [9], but may also occur spontaneously [8]. In a which is widely expressed in renal tissues; these include
previous work, we found a constant ratio of PGE2 to PGD2 glomeruli, arterial walls, thick ascending limbs of Henle’s
when they were nonenzymatically obtained from PGH2 loop, luminal and basolateral membranes of either distal
formed by incubations of AA with isolated COX-1 or
convoluted tubules, and the basolateral membranes ofCOX-2 (4.2 6 0.8 or 4.4 6 1.2, respectively) [11], indicat-
collecting tubules [26–29]. PGH2 released by mesangialing that PGE2 is the thermodynamically favorable iso- cells and also by endothelial cells [11, 30] could counter-mer. In resting RGMCs, we found a ratio of PGE2 to act the vasorelaxant effect of PGI2 and PGE2, particularlyPGD2 of 4.3, similar to that of nonenzymatic isomeriza- under inflammatory conditions in which the release oftion of PGH2, suggesting that PGES activity, if any, was PGH2 is greatly enhanced. Indeed, stable PGH2 analogsvery low in resting cells. Consistently, SnCl2 deviated
contract glomeruli [31] and activation of TXA2/PGH2PGE2 formation toward PGF2a almost completely in
receptors produces renal vasoconstriction and reducescells in resting state. In contrast, IL-1b–treated RGMCs
renal blood flow [32], effects that are in part related toyielded a ratio PGE2 to PGD2 of 8.1 when incubated
potentiation of tubuloglomerular feedback [33]. On thewith labeled AA, suggesting that PGE2 was formed in
other hand, the ability of glomerular cells to undergopart enzymatically. This finding is consistent with the
proliferation and participate in hypertrophy of the glo-fact that PGES is inducible by IL-1 [9, 13]. The concept
merulus may be a critical determinant in the develop-that the PGE2 was only in part formed enzymatically is
ment of progressive glomerulosclerosis [34]. An increasesupported by the finding that the presence of SnCl2 in
in the release of PGH2 by endothelial [11] and mesangialthe incubation mixture results in a substantial deviation
cells caused by pro-inflammatory cytokines such as IL-1bof PGE2 toward PGF2a; 72% of PGE2 was approximately
could be relevant in this process, since TXA2/PGH2 aredeviated toward PGF2a by SnCl2. PGD2 was not detected
mitogens for vascular smooth muscle cells [35–37] andin incubations of human dermal fibroblasts and SnCl2
for mesangial cells [38].diverted PGE2 toward PGF2a by only 20%, since dermal
Despite the fact that caution and more research arefibroblasts possessed high PGES activity, which was con-
required to assess the biological relevance of our findingsfirmed by RT-PCR [13]. Although it was not possible to
in vivo, the present data increase our knowledge aboutdetermine the expression of PGES in RGMC since only
the human gene has been characterized, the present re- the metabolism of AA by mesangial cells.
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